Traded Value$Hims & Hers Health(HIMS.US) holds leading scale in US direct-to-consumer personalized telehealth (~2x the size of many #2 players).
Core moat includes data flywheel (labs with 130+ biomarkers), high customer trust/brand, low churn via subscriptions, and supplier networks. Competitors include Ro/Roman, traditional telehealth, and branded pharma direct channels.
Threats from GLP-1 price competition and compounding regulations are being actively mitigated via branded pivots and diversification. Market share continues expanding in core categories.
@Bridge Buzz SG
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
